Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Growth hormone therapy.

Anurag Bajpai1, P Sn Menon

  • 1Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.

Indian Journal of Pediatrics
|March 11, 2005
PubMed
Summary

Growth hormone (GH) therapy significantly improves height outcomes in children with growth hormone deficiency (GHD). Recombinant GH, administered subcutaneously, is now standard, with higher doses potentially enhancing results but increasing costs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validation of DSD Interpreter, a Mobile Application for Point-of-Care Evaluation of Infants with Atypical Genitalia: Authors' Reply.

Indian journal of pediatrics·2026
Same author

Clinical Course and Determinants of Remission in Children and Adolescents with Prediabetes: Authors' Reply.

Indian journal of pediatrics·2026
Same author

Development and Validation of Puberty Interpreter, a Mobile Clinical Decision-Support Tool for Pubertal Disorders.

Indian journal of pediatrics·2026
Same author

MASLD as a crucial component in the pathogenesis, evaluation and management of type 2 diabetes in Asian Indians.

Diabetes & metabolic syndrome·2026
Same author

Attention-enhanced variational learning for physically informed discovery of exceptionally hard multicomponent bulk metallic glasses.

Nature communications·2026
Same author

Physics-Constrained Constitutive Learning of Rate-Limiting Timescales for Efficient Hydrogen-Based Direct Reduction for Green Steel Making.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Biotechnology

Background:

  • Growth hormone (GH) deficiency (GHD) in children necessitates effective treatment for optimal height.
  • Early GH therapies derived from human pituitary glands posed safety risks, including prion transmission.
  • The advent of recombinant DNA technology revolutionized GH production and safety.

Purpose of the Study:

  • To review the advancements and current practices in GH therapy for pediatric GHD.
  • To discuss the transition from pituitary-derived to recombinant GH and its implications.
  • To evaluate the efficacy, dosing strategies, and expanded indications for GH therapy.

Main Methods:

  • Review of clinical studies and therapeutic guidelines for GH therapy.
  • Analysis of growth velocity data before and during GH treatment.
  • Examination of safety profiles and the shift towards recombinant GH preparations.

Main Results:

  • GH therapy significantly improves final height in children with GHD, often achieving the target height range.
  • Recombinant GH administration (once-daily subcutaneous injection) is the established standard of care.
  • Higher GH doses (e.g., 0.33 mg/kg/week) can further enhance growth velocity (10-12 cm/year initially, sustained at 7-8 cm/year).

Conclusions:

  • GH therapy is a cornerstone in managing pediatric GHD, offering substantial height benefits.
  • Continuous monitoring and individualized dosing are crucial for maximizing therapeutic outcomes.
  • The availability of recombinant GH has expanded its use to various other pediatric growth disorders beyond GHD.

Related Experiment Videos